Search clinical trials for: Upadacitinib (ABT-494)

Total 1536 results

AbbVie (prior sponsor, Abbott)

Completed

A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects

Solid Tumors

United States
Klinikum der Universität Köln

Unknown

Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa (URGE-II)

Surgical Treatment of Urge Incontinence

Germany
Central European Cooperative Oncology Group

Terminated

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Renal Cell Cancer

Austria
Oklahoma State University
University of Oklahoma; University of Minnesota; Case Western Reserve University and other collaborators

Completed

Cognitive and Self-regulatory Mechanisms Of Obesity Study (COSMOS)

Obesity
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C (PEARL-II)

Chronic Hepatitis C Infection
AbbVie

Active, not recruiting

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Japan
University of Erlangen-Nürnberg
Deutsche Rentenversicherung

Completed

A Bio-psycho-social Exercise Program (RÜCKGEWINN) for Chronic Low Back Pain in Rehabilitation Aftercare (RÜCKGEWINN)

Low Back Pain

Germany
AbbVie

Recruiting

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis Suppurativa

United States, Australia, Canada, Germany, Greece, Japan, Spain, Puerto Rico
University Hospital Inselspital, Berne
Swiss National Science Foundation

Completed

The Effects of Growth Hormone (GH) on Lipid Depots

Growth Hormone Deficiency

Switzerland
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
Steven J Isakoff, MD, PhD
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Abbott

Active, not recruiting

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Breast Cancer | Metastatic Breast Cancer | BRCA1 Gene Mutation | brca2 Gene Mutation

United States
AbbVie (prior sponsor, Abbott)

Completed

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)

Hepatitis C | Chronic Hepatitis C Infection | HCV | Hepatitis C Genotype 1

United States, Puerto Rico
AbbVie (prior sponsor, Abbott)

Completed

An Evaluation of the Biodistribution and Imaging Characteristics of ABT-806i (111In-ABT-806) in Subjects With Advanced Solid Tumor Types

Advanced Solid Tumors

Australia
Richard Zellars

Completed

Pre-Operative Radiation and Veliparib for Breast Cancer

Breast Cancer

United States
AbbVie

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) (SELECT-TAK)

Takayasu Arteritis (TAK)

Argentina, Brazil, China, Japan, Korea, Republic of, Turkey
AbbVie

Active, not recruiting

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

United States, Australia, Austria, Canada, France, Germany, Italy, Spain
AbbVie

Completed

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

HCV | Hepatitis C Infection | Genotype 4
AbbVie

Completed

ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis

Chronic Hepatitis C Virus (HCV)
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
AbbVie

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection (PEARL-IV)

Chronic Hepatitis C Infection
ResMed
Clinical Trial Center North Hamburg Germany; CRI-The Clinical Research Institute...

Terminated

European Home Mechanical Ventilation Registry (EHMVR)

Pulmonary Disease, Chronic Obstructive | Amyotrophic Lateral Sclerosis | Muscular Dystrophies | Duchenne Muscular Dystrophy | Myotonic Dystrophy | Spinal Cord Injury | Obesity Hypoventilation Syndrome | Kyphoscoliosis | Congenital Central Hypoventilation Syndrome | Myopathies

Germany
Medical University of Vienna
AstraZeneca

Completed

Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. (EXENDA)

Type2 Diabetes | Steatosis, Liver

Austria
AbbVie (prior sponsor, Abbott)

Terminated

This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

United States, Poland, Russian Federation, South Africa, Ukraine, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Study of ABT-767 in Subjects With Breast Cancer 1 and Breast Cancer 2 (BRCA 1 and BRCA 2) Mutations and Solid Tumors or High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Fallopian Tube | Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and Ovarian

Netherlands
AbbVie

Terminated

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Australia
AbbVie

Completed

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

Relative Bioavailability

United Kingdom
Abbott

Terminated

A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Alzheimer's Disease

United States
Abbott

Terminated

A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's Disease

Alzheimer's Disease

United States
Abbott

Completed

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

Healthy

United States
Anbogen Therapeutics, Inc.

Recruiting

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

Non Small Cell Lung Cancer | Advanced Solid Tumor | HER2 Mutations

Taiwan
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis (TURQUOISE-II)

Compensated Cirrhosis | Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Brain Diseases | Central Nervous System Diseases | Neoplasm Metastasis | Brain Neoplasms | Nervous System Neoplasms

United States, Canada, Puerto Rico
AbbVie

Terminated

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Alzheimer's Disease

United States
AbbVie

Completed

Study Of Oral Elagolix Tablets To Assess the Tolerability and Change in Disease Symptoms in Adult Female Participants With Moderate to Severe Endometriosis-associated Pain (ENDORSE)

Endometriosis

Israel
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults (MALACHITE II)

Chronic Hepatitis C Infection
Alexandra Kautzky-Willer
Bayer

Recruiting

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism (Test2Func)

Fatty Liver | Hypogonadism, Male | Overweight/Obesity | Prediabetes/Type2 Diabetes Mellitus

Austria
AbbVie

Completed

Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection (GIFT I)

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Infection
AbbVie (prior sponsor, Abbott)

Completed

ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

Chronic Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)

United States, Australia, Canada, France, Germany, New Zealand, Puerto Rico, Spain, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection (PEARL-III)

Chronic Hepatitis C Infection
Patrick Wen, MD
Bristol-Myers Squibb

Active, not recruiting

Surgical Nivolumab And Ipilimumab For Recurrent GBM

Glioblastoma | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States
William Beaumont Hospitals

Completed

Impact of Pharmacy Clinic on Diabetes Management (PharmaMD)

Diabetes Mellitus, Type 2

United States
Adana Numune Training and Research Hospital

Completed

Atopic Diseases & Human Papilloma Virus

Human Papilloma Virus | Atopic Asthma | Atopic Disorders

Turkey
University of Vermont Medical Center

Terminated

Risk Stratification in Primary Care Combined With Stratified-specific Physical Therapy Care for Low Back Pain

Low Back Pain

United States
Bristol-Myers Squibb
Pfizer

Completed

Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy (RE-FIT)

Anticoagulation

Italy
Wills Eye

Completed

Using a Type of Blue Dye to Observe Bleb Function During Cataract Surgery

Glaucoma

United States

3

Subscribe